RNA sequencing to predict response to neoadjuvant anti-HER2 therapy a secondary analysis of the NeoALTTO randomized clinical trial.
Times cited: 3
Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-Positive metastatic breast cancer.
Clinical Cancer Research.
Times cited: 21
Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
Annals of Oncology.
Times cited: 404
Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotype ACA125: Immunological Response and Survival (Phase Ib/II).
Times cited: 107